Ping An Healthcare (1833.HK, HKSE) HK$13.91 pre-market ahead of earnings: guidance key

We see 1833.HK stock at HK$13.91 in Hong Kong pre-market on 17 Feb 2026, with earnings due 18 Feb 2026. The main market focus is on revenue growth and margin guidance from Ping An Healthcare and Technology Company Limited (1833.HK) on the HKSE. Investors will weigh near-term guidance against a stretched valuation, with a trailing PE near 142.10 and EPS of 0.10. Volume is light at 1,375,492 shares today, and the stock sits between its 50-day average HK$15.02 and 200-day average HK$13.57.

Earnings preview for 1833.HK stock

Ping An Healthcare and Technology Company Limited (1833.HK) reports results on 18 Feb 2026 and guidance will set the tone. Analysts expect commentary on online consultation growth and medicine sales mix. We will watch gross margin changes and operating leverage after recent cost controls. Short-term price moves often follow management guidance and revenue growth beats.

Valuation and financials for 1833.HK stock

The stock trades at HK$13.91 with market cap HKD 30218912747.00 and EPS 0.10. Reported PE is 142.10 and PB is 2.51. Cash per share is 1.75 and the current ratio is 3.15, showing liquidity strength. Revenue per share TTM is 2.62 and net income per share TTM is 0.08. These ratios imply growth expectations are priced in and valuation is high versus Healthcare sector averages.

Meyka AI rates 1833.HK with a score out of 100 and forecast for 1833.HK stock

Meyka AI rates 1833.HK with a score of 70.06 out of 100, grade B+, suggestion BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly target of HK$21.99, implying an upside of 58.12% vs the current HK$13.91. Forecasts are model-based projections and not guarantees.

Technicals and trading setup for 1833.HK stock

Technicals show near-term weakness with RSI 35.90 and MACD negative. Bollinger middle band is HK$14.74 and lower band HK$13.05. Average volume is 16,507,602.00 shares, and today’s volume is 1,375,492.00, underlining thin trading. Short-term traders may watch a break below HK$13.61 day low or a move above HK$13.92 for momentum clues.

Catalysts, risks and sector context for 1833.HK stock

Key catalysts include 18 Feb earnings, margin guidance, and consumer health product growth. Sector context: Healthcare peers show stronger margins but higher PE averages. Risks include slowing online patient growth, regulatory changes in China, and high valuation sensitivity. Cash position and low debt mitigate balance sheet risk, but operating margins remain thin and volatile.

Near-term scenarios and 1833.HK stock price targets

Base case short-term target aligns with Meyka monthly forecast HK$14.06 and quarterly target HK$18.56. Conservative near-term price target: HK$14.00. Bull case 12-month price target: HK$21.99. Downside risk exists to the HK$10.00–HK$12.00 range if guidance misses and market sentiment falls.

Final Thoughts

The 17 Feb 2026 pre-market picture for 1833.HK stock shows a focus on tomorrow’s earnings and guidance. At HK$13.91, the stock trades at a high PE of 142.10, reflecting growth priced into the share price. Meyka AI’s forecast model projects HK$21.99 for the year, implying 58.12% upside versus the current price, but that projection is model-based and not guaranteed. Short-term traders should watch guidance on revenue mix and gross margins on 18 Feb 2026. Longer-term investors should weigh strong liquidity and low debt against elevated valuation and sector peers. Use stop-loss discipline and monitor volume and management commentary. For live quotes and further data, see Meyka AI’s market page and company filings at Ping An Healthcare site and sector comparison on Investing.com. Meyka AI is the AI-powered market analysis platform used to generate these insights.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.